Iteos Therapeutics Inc Total Assets
Iteos Therapeutics Inc total assets. Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) holds total assets worth $623.08 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Iteos Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Iteos Therapeutics Inc (2018–2024)
Total assets of Iteos Therapeutics Inc from 2018 to 2024. This chart illustrates how Iteos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Iteos Therapeutics Inc stock quote for real-time trading data and today's change.
Iteos Therapeutics Inc - Asset Composition Analysis
Iteos Therapeutics Inc Total Assets Breakdown (December 2024)
Iteos Therapeutics Inc total assets breakdown as of December 2024. Iteos Therapeutics Inc's total assets of $623.08 Million consist of 74.2% current assets and 25.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $3.69 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ITOS working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iteos Therapeutics Inc's current assets represent 74.2% of total assets in 2024, a decrease from 86.4% in 2018.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 80.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Iteos Therapeutics Inc Competitors by Total Assets
Key competitors of Iteos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Iteos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.53 | 18.08 | 33.49 |
| Quick Ratio | 7.53 | 18.08 | 33.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $458.72 Million | $591.94 Million | $335.41 Million |
Iteos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Iteos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | $686.98 Million |
| Market Capitalization | $448.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Iteos Therapeutics Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Iteos Therapeutics Inc's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Iteos Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $686.98 Million | +2.90% |
| 2023-12-31 | $667.59 Million | -11.58% |
| 2022-12-31 | $754.99 Million | -14.66% |
| 2021-12-31 | $884.71 Million | +156.77% |
| 2020-12-31 | $344.56 Million | +1020.73% |
| 2019-12-31 | $30.74 Million | +12.24% |
| 2018-12-31 | $27.39 Million | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more